Seed, early, and early-growth companies. The list is a preference, not a fence. A business outside it can still be worth a conversation if the people and the economics are serious.
With an investment, we take an active supporting role: developing the business, widening the opportunity, and working with management on the decisions that determine whether the company gets through the next stage.
The same posture applies when the assignment is a sale, an acquisition, or a restructuring of the capital structure. Advice is useful only if someone is willing to stay in the work.
Advertising and marketing technology. Software and platforms that help advertisers reach people, measure what happened, and run the work of marketing with less waste.
Financial technology. Software and platforms that change how money, credit, payments, risk, or financial operations actually move.
Health and life sciences technology. Devices, software, and solutions used by clinicians, operators, or patients — where the buyer is identifiable and the path to use is real.
Companies in financial services themselves, not only the software around them. We look for a clear customer, a compliance posture that can survive growth, and a reason the firm should exist beside incumbents.
Pharmaceuticals, biotechnology, medical devices, and other health-product innovation. This is a part of the practice with a long personal history on the team, including company-building, product acquisitions, and financing.